Top

Published in:

01-07-2016 | Original Article

⁶⁸Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer

Early efficacy after primary therapy

Authors: Christoph Henkenberens, M.D., Christoph A. von Klot, M.D., Tobias L. Ross, Ph.D., Frank M. Bengel, M.D., Hans-Jürgen Wester, Ph.D., Axel S. Merseburger, M.D., Jens Vogel-Claussen, M.D., Hans Christiansen, M.D., Thorsten Derlin, M.D.

Published in: Strahlentherapie und Onkologie | Issue 7/2016

Abstract

Purpose

The goal of this work was to evaluate the early efficacy of ⁶⁸Ga-PSMA ligand PET/CT imaging for radiotherapy of locally recurrent and/or oligometastatic prostate cancer.

Patients and methods

A total of 29 patients with biochemical recurrence received a ⁶⁸Ga-PSMA ligand PET/CT for restaging of disease, followed by 3D conformal radiotherapy of metastases or intensity-modulated radiation therapy of the prostate bed. Prostate-specific antigen (PSA) levels and imaging procedures served as the reference standard to assess the treatment efficacy.

Results

PET/CT was positive in 96.6% of patients and revealed that 13.8% of patients had locally recurrent disease, 58.6% had isolated lymph node metastases, 20.7% had isolated bone metastases, and 3.4% showed lymph node metastases and a vertebral metastasis. The median follow-up was 8.3 months (range 3.0–17.3 months). The median PSA prior to radiotherapy was 1.47 ng/ml (range 0.52–32.01 ng/ml) and showed a statistically significant decrease to 0.58 ng/ml (range < 0.07 to 6.33 ng/ml, p < 0.001). Two patients (6.8%) developed progressive disease outside the radiation field after 12.0 and 12.7 months, yielding a local control rate of 100% at the median follow-up. No grade III acute toxicity or late toxicity grade II was observed. Only 2 patients (6.8%) reported persisting grade I diarrhoea according to the LENT-SOMA criteria 3 months after radiotherapy. Deterioration of the urinary or faecal continence was not observed.

Conclusion

Preliminary results in the presented cohort suggest that radiotherapy based on ⁶⁸Ga-PSMA ligand PET/CT yields effective local control and significant treatment response in terms of PSA levels in the absence of clinically important side effects. Furthermore, this approach delayed the necessity of androgen deprivation therapy or systemic therapy.

Grosu A‑L, Piert M, Weber MA et al (2005) Positron emission tomography for radiation treatment planning. Strahlenther Onkol 181(8):483–499CrossRefPubMed

Wondergem M, Zant FM van der, Poeg T van der et al (2013) A literature review of 18 F-fluoride PET/CT and 18 F-choline or 11 C-cholie PET/CT for detection of bone metastasis in patients with prostate cancer. Nucl Med Commun 34(10):935–945CrossRefPubMed

Umbehr MH, Müntener M, Hany T et al (2013) The role of 11 C-choline and 18 F-fluorocholine positron emission tomography (PET) and PET/CT in prostate cancer: a systematic review and meta-analysis. Eur Urol 64(1):106–117CrossRefPubMed

Decaestecker K, Meerleer G, Lambert B et al (2014) Repeated stereotactic body radiotherapy for oligometastatic prostate cancer recurrence. Radiat Oncol 12(9):135. doi:10.1186/1748-717X-9-135CrossRef

Eyben FE von, Kairemo K (2014) Meta-analysis of 11 C-choline and 18 F-choline PET/CT for management of patients with prostate cancer. Nucl Med Commun 35(3):221–230CrossRef

Picchio M, Berardi G, Fodor A et al (2014) (11)C-Choline PET/CT as a guide to radiation treatment planning of lymph-node relapses in prostate cancer patients. Eur J Nucl Med Mol Imaging 41(7):1270–1279

Jackson WC, Johnson SB, Feng FY et al (2015) Salvage radiation therapy improves metastasis-free survival for clinically aggressive and indolent prostate cancer recurrences after radical prostatectomy. Am J Clin Oncol 38(4):367–372CrossRefPubMed

Ost P, Decaestecker K, Lambert B et al (2013) Prognostic factors influencing prostate cancer-specific survival in non-castrate patients with metastatic prostate cancer. Prostate 74(3):297–305CrossRef

Mottet N, Bellmunt J, Bolla M et al (2011) EAU guidelines on prostate cancer part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 59(4):572–583CrossRefPubMed

10.

Mease RC, Foss CA, Pomper MG (2013) PET imaging in prostate cancer: focus on prostate-specific membrane antigen. Curr Top Med Chem 13(8):951–962CrossRefPubMedPubMedCentral

11.

Chang SS, O’Keefe DS, Bacich DJ et al (1999) Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 5(10):2674–2681PubMed

12.

Afshar-Oromieh A, Zechman CM, Malcher A et al (2014) Comaparison of PET imaging with a (68) Ga-labelled PSMA ligand and (18)F-choline-based PET/CT for the diagnosis of recurrent prostate cancer. Eur J Nucl Mol Imaging 41(1):11–20CrossRef

13.

Weineisen M, Schottelius M, Simecek J et al (2015) 68 Ga- and 177 Lu-labeled PSMA I&T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med 56(8):1169–1176CrossRefPubMed

14.

Martin R, Jüttler S, Müller M et al (2014) Cationic eluate pretreatment for automated synthesis of [⁶⁸GA] CPCR4.2. Nucl Med Biol 41(1):84–89CrossRefPubMed

15.

National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) v.4.0. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Accessed 16 Oct 2015

16.

Pavy JJ, Denekamp J, Letschert J et al (1995) EORTC Late Effects Working Group. Late effects toxicity scoring: the SOMA scale. Int J Radiat Oncol Biol Phys 31(5):1043–1047CrossRefPubMed

17.

Schweizer MT, Zhou XC, Wang H et al (2013) Metastasis-free survival is associated with overall survival in men with PSA-recurrent prostate cancer treated with deferred androgen deprivation therapy. Ann Oncol 24(11):2881–2886CrossRefPubMedPubMedCentral

18.

Afshar-Oromieh A, Avtzi E, Giesel FL et al (2015) The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42(2):197–209CrossRefPubMed

19.

Giesel FL, Fiedler H, Stefanova M et al (2015) PSMA PET/CT with Glu-urea-Lys-(Ahx)-[68 Ga(HBED-CC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer. Eur J Nucl Med Mol Imaging 42(12):1794–1800CrossRefPubMedPubMedCentral

20.

Cimitan M, Bortulus R, Morassut S et al (2006) [18 F]fluorcholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 33(12):1387–1398CrossRefPubMed

21.

Ceci F, Uprimny C, Nilica B et al (2015) (68)Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate? Eur J Nucl Med Mol Imaging 42(8):1784–1794CrossRef

22.

Merseburger AS, Hammerer P, Rozet F et al (2014) Androgen deprivation therapy in castrate-resistant prostate cancer: how important is GnRH agonist backbone therapy. World J Urol 33(8):1079–1085CrossRefPubMedPubMedCentral

23.

Punnen S, Cooperberg MR, D’Amic AV et al (2013) Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature. Eur Urol 64(6):905–915CrossRefPubMed

24.

Agarwal PK, Sadetsky N, Konety BR et al (2008) Treatment failure after primary salvage therapy for prostate cancer: likelihood, patterns of care, outcomes. Cancer 112(2):307–314CrossRefPubMed

25.

Yu EY, Gulati R, Telesca D et al (2010) Duration of first off-treatment interval is prognostic for time to castration resistance an death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation. J Clin Oncol 28(16):2668–2673CrossRefPubMedPubMedCentral

26.

Bhandari MS, Crook J, Hussain M (2005) Should intermittent androgen deprivation be uses routinely in clinical practice? J Clin Oncol 23(32):8212–8218CrossRefPubMed

27.

Jilg CA, Rischke HC, Reske SN (2012) Salvage lymph node dissection with adjuvant radiotherapy for nodal recurrence of prostate cancer. J Urol 188(6):2190–2197CrossRefPubMed

28.

Rischke HC, Schultze-Seemann, Wieser G et al (2015) Adjuvant radiotherapy after salvage lymph node dissection because of nodal relapse of prostate cancer versus salvage lymph node dissection only. Strahlenther Onkol 191(4):310–320CrossRefPubMed

29.

Suardi N, Gandaglia G, Gallina A et al (2015) Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. Eur Urol 67(2):299–309CrossRefPubMed

30.

Rinnab L, Mottaghy FM, Simon J et al (2008) [11 C] Choline PET/CT for targeted salvage lymph node dissection in patients with biochemical recurrence after primary curative therapy for prostate cancer. Preliminary results of a prospective study. Urol Int 81(2):191–197CrossRefPubMed

31.

Casamassima F, Masi L, Menichelli C et al (2011) Efficacy of eradicative radiotherapy for limited nodal metastases detected with choline PET scan in prostate cancer patients. Tumori 97(1):49–55PubMed

32.

Jereczek-Fossa BA, Beltramo G et al (2012) Robotic image-guided stereotactic radiotherapy, for isolated recurrent, lymph node or metastatic prostate cancer. Int J Radiat Oncol Biol Phys 82(2):889–897CrossRefPubMed

33.

Muacevic A, Kufeld M, Bist C et al (2011) Safety and feasibility of image-guided robotic radiosurgery for patients with limited bone metastases in prostate cancer patients. Urol Oncol 31(4):455–460CrossRefPubMed

34.

Schick U, Jorcano S, Nouet P et al (2013) Androgen deprivation and high-dose radiotherapy for oligometastatic prostate cancer patients with less than five regional and/or distant metastasis. Acta Oncol 52(8):1622–1628CrossRefPubMed

35.

Ahmed KA, Barney BM, Davis BJ et al (2012) Stereotactic body radiation therapy in the treatment of oligometastatic prostate cancer. Front Oncol 22(2):215. doi:10.3389/fonc.2012.00215

36.

Niyazi M, Bartenstein P, Belka C et al (2010) Choline PET based dose-painting in prostate cancer – modelling of dose effects. Radiat Oncol 18(5):23. doi:10.1186/1748-717X-5-23CrossRef

Title: 68Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer
Early efficacy after primary therapy
Authors: Christoph Henkenberens, M.D.
Christoph A. von Klot, M.D.
Tobias L. Ross, Ph.D.
Frank M. Bengel, M.D.
Hans-Jürgen Wester, Ph.D.
Axel S. Merseburger, M.D.
Jens Vogel-Claussen, M.D.
Hans Christiansen, M.D.
Thorsten Derlin, M.D.
Publication date: 01-07-2016
Publisher: Springer Berlin Heidelberg
Published in: Strahlentherapie und Onkologie / Issue 7/2016
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-016-0982-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

⁶⁸Ga-PSMA ligand PET/CT-based radiotherapy in locally recurrent and recurrent oligometastatic prostate cancer

Early efficacy after primary therapy

Abstract

Purpose

Patients and methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Patients and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2016

SHARP hypofractionated stereotactic radiotherapy is well tolerated in prostate cancer

High dose-rate endoluminal brachytherapy for primary and recurrent esophageal cancer

Risk of biochemical recurrence and timing of radiotherapy in pT3a N0 prostate cancer with positive surgical margin

Inclined head position improves dose distribution during hippocampal-sparing whole brain radiotherapy using VMAT

Überlebensvorteil durch konsolidierende Strahlentherapie bei Patienten mit diffusem großzelligen B‑Zell-Lymphom in den Frühstadien

Bei diffus großzelligen B‑Zell-Lymphomen des Magens nach Komplett-Remission nach Chemotherapie konsolidierende Strahlentherapie empfohlen